A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects with Select Advanced Solid Tumors. The main goals of this study are to: * Find the recommended dose of TS-104 that can safely be given to participants * Learn more about the side effects of TS-104 * Learn more about the effectiveness of TS-104 * Learn more about the pharmacokinetics of TS-104

Trial Details

NCT ID
NCT07814248
Phase
PHASE1
Sponsor
TwoStep Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • TS-104
Locations (sample)
  • Maumee, Ohio, United States|41.56283,-83.65382
  • Portland, Oregon, United States|45.52345,-122.67621
  • Fairfax, Virginia, United States|38.84622,-77.30637

Key Eligibility Criteria

  • Males \& females ≥18 years of age at the time of consent
  • Willingness to provide written informed consent, according to local guidelines.
  • Subjects who have histologically or cytologically documented, unresectable locally advanced, or metastatic solid malignancy that is progressing or …
  • Non-small cell lung cancer (NSCLC)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →